Cited by

• Peptides: Prospects for Use in the Treatment of COVID-19.

  Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Khavinson V, et al. Molecules. 2020 Sep 24;25(19):4389. doi: 10.3390/molecules25194389. Molecules. 2020. PMID: 32987757 Free PMC article. Review.
• [COVID-19 and its relationship with hypertension and cardiovascular disease].

  Salazar M, Barochiner J, Espeche W, Ennis I. Salazar M, et al. Hipertens Riesgo Vasc. 2020 Oct-Dec;37(4):176-180. doi: 10.1016/j.hipert.2020.06.003. Epub 2020 Jun 18. Hipertens Riesgo Vasc. 2020. PMID: 32591283 Free PMC article. Review. Spanish.
• An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection.

  Devaux CA, Camoin-Jau L. Devaux CA, et al. Front Microbiol. 2022 Nov 28;13:1042200. doi: 10.3389/fmicb.2022.1042200. eCollection 2022. Front Microbiol. 2022. PMID: 36519165 Free PMC article. Review.
• Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers and Mortality in Patients with Hypertension Hospitalized with COVID-19.

  Abedtash A, Taherkhani M, Shokrishakib S, Nikpour S, Taherkhani A. Abedtash A, et al. J Tehran Heart Cent. 2021 Jul;16(3):95-101. doi: 10.18502/jthc.v16i3.8185. J Tehran Heart Cent. 2021. PMID: 35633826 Free PMC article.
• Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury.

  Ventura D, Carr AL, Davis RD, Silvestry S, Bogar L, Raval N, Gries C, Hayes JE, Oliveira E, Sniffen J, Allison SL, Herrera V, Jennings DL, Page RL 2nd, McDyer JF, Ensor CR. Ventura D, et al. Open Forum Infect Dis. 2021 Apr 4;8(10):ofab170. doi: 10.1093/ofid/ofab170. eCollection 2021 Oct. Open Forum Infect Dis. 2021. PMID: 34642634 Free PMC article. Review.